curasan will invest in the targeted expansion of sales and marketing activities in the U.S. and China. The company markets CERASORB® bone void filler products.
The company expects FDA clearance of its CERASORB Ortho Foam bone regeneration material by the end of 2016, to be followed by an expected launch via new sales partners in 1Q17. Its first 510(k) was achieved in 2002, for Cerasorb Ortho Calcium Sulfate Preformed Pellets.
The step into China will also include work with new and established sales partners. The company has present approval to market its dental products in that region, and curasan will invest in additional approvals in for its CERASORB orthopedics portfolio. The latter is expected in 2020.
curasan will invest in the targeted expansion of sales and marketing activities in the U.S. and China. The company markets CERASORB® bone void filler products.
The company expects FDA clearance of its CERASORB Ortho Foam bone regeneration material by the end of 2016, to be followed by an expected launch via new sales partners in 1Q17. Its...
curasan will invest in the targeted expansion of sales and marketing activities in the U.S. and China. The company markets CERASORB® bone void filler products.
The company expects FDA clearance of its CERASORB Ortho Foam bone regeneration material by the end of 2016, to be followed by an expected launch via new sales partners in 1Q17. Its first 510(k) was achieved in 2002, for Cerasorb Ortho Calcium Sulfate Preformed Pellets.
The step into China will also include work with new and established sales partners. The company has present approval to market its dental products in that region, and curasan will invest in additional approvals in for its CERASORB orthopedics portfolio. The latter is expected in 2020.
Copy to clipboard 
